If INCY is a top pick for 2013 - why wait until 2013 to buy INCY
Incyte Corporation (NASDAQ:INCY): JMP Securities expects Incyte Corporation to benefit from several important clinical data catalysts and an acceleration in revenue from their Jakafi drug for the treatment of Myelofibrosis. The firm recommends buying shares of Incyte in 2013.
Why wait till 2013 when maybe it cost more per share? Why not buy now at a discount?